These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31741178)

  • 21. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How long should antipsychotic treatment be continued after a single episode of schizophrenia?
    Emsley R; Kilian S; Phahladira L
    Curr Opin Psychiatry; 2016 May; 29(3):224-9. PubMed ID: 26967313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms.
    Takeuchi H; Suzuki T; Uchida H; Watanabe K; Mimura M
    Schizophr Res; 2012 Feb; 134(2-3):219-25. PubMed ID: 22154594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol.
    Weller A; Gleeson J; Alvarez-Jimenez M; McGorry P; Nelson B; Allott K; Bendall S; Bartholomeusz C; Koval P; Harrigan S; O'Donoghue B; Fornito A; Pantelis C; Paul Amminger G; Ratheesh A; Polari A; Wood SJ; van der El K; Ellinghaus C; Gates J; O'Connell J; Mueller M; Wunderink L; Killackey E
    Early Interv Psychiatry; 2019 Dec; 13(6):1345-1356. PubMed ID: 30488637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
    Dold M; Samara MT; Li C; Tardy M; Leucht S
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD009831. PubMed ID: 25592299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).
    Moncrieff J; Lewis G; Freemantle N; Johnson S; Barnes TRE; Morant N; Pinfold V; Hunter R; Kent LJ; Smith R; Darton K; Horne R; Crellin NE; Cooper RE; Marston L; Priebe S
    BMJ Open; 2019 Nov; 9(11):e030912. PubMed ID: 31780589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis.
    Bowtell M; Eaton S; Thien K; Bardell-Williams M; Downey L; Ratheesh A; Killackey E; McGorry P; O'Donoghue B
    Schizophr Res; 2018 May; 195():231-236. PubMed ID: 29066258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.
    Wunderink L; Nieboer RM; Wiersma D; Sytema S; Nienhuis FJ
    JAMA Psychiatry; 2013 Sep; 70(9):913-20. PubMed ID: 23824214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort.
    Liu CC; Hsieh MH; Chien YL; Liu CM; Lin YT; Hwang TJ; Hwu HG
    Psychol Med; 2023 Nov; 53(15):7078-7086. PubMed ID: 36896797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Examining the effectiveness of antipsychotic medication in first-episode psychosis.
    Taylor M; Cavanagh J; Hodgson R; Tiihonen J
    J Psychopharmacol; 2012 May; 26(5 Suppl):27-32. PubMed ID: 22337711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.
    Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu A; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Romeo R; Gray R
    Health Technol Assess; 2018 Nov; 22(67):1-62. PubMed ID: 30507375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perceptions of relapse risks following first-episode psychosis and attitudes towards maintenance medication: a comparison between nursing and social work professionals.
    Chan KK; Chin QP; Tang JY; Longenecker J; Hui CL; Chiu CP; Lam MM; Wong GH; Chen EY
    Early Interv Psychiatry; 2011 Nov; 5(4):324-34. PubMed ID: 21521490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic consequences of alternative medication strategies in first episode non-affective psychosis.
    Stant AD; TenVergert EM; Wunderink L; Nienhuis FJ; Wiersma D
    Eur Psychiatry; 2007 Sep; 22(6):347-53. PubMed ID: 17418538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design.
    Nasib LG; Sommer IE; Winter-van Rossum I; de Vries J; Gangadin SS; Oomen PP; Judge G; Blom RE; Luykx JJ; van Beveren NJM; Veen ND; Kroken RA; Johnsen EL
    Trials; 2020 Jun; 21(1):492. PubMed ID: 32513294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.
    Takeuchi H; Siu C; Remington G; Fervaha G; Zipursky RB; Foussias G; Agid O
    Neuropsychopharmacology; 2019 May; 44(6):1036-1042. PubMed ID: 30514883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial.
    Hui CLM; Honer WG; Lee EHM; Chang WC; Chan SKW; Chen ESM; Pang EPF; Lui SSY; Chung DWS; Yeung WS; Ng RMK; Lo WTL; Jones PB; Sham P; Chen EYH
    Lancet Psychiatry; 2018 May; 5(5):432-442. PubMed ID: 29551618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.